Diagnostic test will provide rapid
results pen-side, a huge advantage over PCR and other tests which
may take up to five days to return results
ALAMEDA,
Calif., April 23, 2024 /PRNewswire/ -- Alveo
Technologies, Inc. (Alveo), a leader in molecular sensing and
diagnostics with its proprietary technology platform, today
announced a partnership with NYtor B.V (The Netherlands), an innovative assay
developer, to create a rapid, accurate, pen-side test that will
detect the dominant swine flu strains, including H1N1, H1N2 and
H3N2.
In the US, pork industry management systems regularly move pigs
through different stages of production such as the nursery, growers
and finishers. Transitions between stages need to occur on time to
make room for the next group of animals entering the next stage,
and knowing whether animals are infected prior to transport is
critical for good health management. If a group of infected pigs
are brought into a new facility, the virus can spread rapidly
through susceptible swine. Even worse, newly infected swine could
be moved to additional facilities, spreading swine flu throughout
the new destination.
The economic consequences of swine flu are severe. Infected pigs
in the growing phase will see a production loss that will border on
12% to 15%, and if these animals are coinfected with other diseases
like porcine reproductive and respiratory syndrome (PRRS) virus,
then losses can approach 30% to 40%.
Currently, PCR tests provide results in a best-case scenario of
24-to-48 hours but wait times of up to five days are more common,
because samples must be shipped to a laboratory for processing. As
a result, it's nearly impossible to definitively know the flu
status of pigs prior to transport.
A rapid, in-the-field test that's extremely
precise
The Alveo platform, including its mobile app, Alveo
Sense, is a rapid, handheld, reusable, and rugged multiplexed
molecular diagnostic device. It pairs advanced molecular assays
with cloud-enabled data analytics to provide highly accurate and
sensitive real-time detection, analysis, and diagnosis of diseases,
pathogens, and contaminants. The platform employs Alveo's globally
patented direct-electrical sensing approach to pathogen
identification, leveraging loop-mediated isothermal amplification
(LAMP). This portable molecular lab can deliver rapid test results
at the point-of-need or in the field. Alveo's platform also
provides geotagged results that can be uploaded to the cloud to
give a real-time view of national outbreaks and inform
response.
NYtor is developing swine flu assays for the Alveo platform that
will enable operations to monitor the flu status of their animals
in real time with rapid, highly accurate pen-side tests. As a
result, they will be able to detect and stop the spread of swine
flu before multiple facilities are infected, preventing millions of
dollars in lost productivity.
"Combining our custom LAMP-based dedicated assays with the Alveo
platform will create a strong market solution to fill a need in the
pork production industry," said Han
Zendman, CEO of NYtor.
"Just last year, Alveo announced a partnership program that
would enable companies in agriculture and public health to build
accurate, rapid, in-the-field tests to detect a wide array of
pathogens," said Shaun Holt, CEO of
Alveo. "That partnership strategy is delivering even greater
results than we anticipated, with tests in development for Avian
influenza and now, for swine flu. Thanks to our platform and the
joint development effort with NYtor, pork producers will soon have
the means to monitor flu status of their animals in real time."
About Alveo
Alveo is the first company to make molecular detection and
diagnostics universally accessible – on the farm, in the field, in
the clinic, or in the manufacturing plant – helping prevent or
significantly limit the destructive impact of viruses, fungi,
bacteria, and other pathogens by detecting earlier at the point of
need. Alveo's rugged and portable, multiplex-capable diagnostic
platform employs a patented method of direct electrical sensing of
nucleic acid amplification to provide affordable, rapid, and
accurate results. By enabling early pathogen detection, Alveo helps
manage global health, food security, and supply chain resiliency by
providing actionable insights at lightspeed. Know Sooner, Act
Faster™ with Alveo. For more, visit:
https://www.alveotechnologies.com/.
Media contact
Jeff
Miller
Account Director
541-207-6413
jeff@marketstreetgrp.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alveo-technologies-partners-with-nytor-to-develop-rapid-molecular-test-for-the-dominant-swine-flu-strains-302118198.html
SOURCE Alveo Technologies